References
- Santos e. e., Miller V. S., Roach E. S. Neurocutaneous Syndromes. In: Bradley W. G., Daroff R. B., Fenichel G. M., Jankovic J. (eds). Neurology in Clinical Practice-The Neurological Disorders. 4th Edition. Philadelphia: Elsevier Saunders 2004 :1873–1877.
- Cinamon U., Avinoach I., Harell M. Neurofibromatosis type 1, hyperparathyroidism, and osteosarcoma: interplay ? Eur Arch Otorhinolaryngol, 2002, 259 (10): 540–542.
- Kearns A. E., Tompson G. B. Medical and surgical management of hyperparathyroidism. Mayo Clin Proc, 2002, 77: 87–91.
- Moiton M. P., Bijou F., Vargas F., Valentino R., Gruson D., Hilbert G., Benissan G., Cardinaud J. P. Association of type 1 neurofibromatosis and primary hyperparathyroidism. Presse Med, 2002, 31: 1604–5.
- Duquenne M., Klein M., Duiez T., Hadjadi S., Weryha G., Leclere J. Hyperparathyroidism in a patient with neurofibromatosis associated with Steinert’s disease. Ann Med Interne, 1994, 145: 505–507.
- Chakrabarti S., Murugesan A., Arida E. J. The association of neurofibromatosis and hyperparathyroidism. Am J Surg, 1979, 137: 417–420.
- Carney J. A. Familial multiple endocrine neoplasia: the first 100 years. Am J Surg Pathol, 2005, 29: 254–274.
- Kuorilehto T., Poyhonen M., Bloiqu R., Heikkinen J., Vaananen K., Peltonen J. Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body. Osteoporos Int, 2005, 16: 928–936.
- Wu X., Estwick S. A., Chen S., Yu M., Ming W., Nebesio T. D., Li Y., Yuan J., Kapur R., Ingram D., Yoder M. C., Yang F. C. Neurofibromin plays a critical role in modulating osteoblast differentiation of mesenchymal stem/progenitor cells. Hum Mol Genet, 2006, 15: 2837–2845.
- Abdel-Wanis M. E., Kawahara N., Tomita K. The association of neurofibromatosis 1 and spinal deformity with primary hyper-parathyroidism and osteomalacia: might melatonin have a role ? J Orthop Sci, 2001, 6: 193–198.